Login / Signup

Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.

Bernard Sean RegidorDilawer SiddiqiBethany Marie BeattyMarissa-Skye GoldwaterScott JewSean BujarskiRegina SwiftSusanna KimJames R Berenson
Published in: European journal of haematology (2022)
Keyphrases
  • monoclonal antibody
  • end stage renal disease
  • multiple myeloma
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • nk cells